Project and CDTI Group Coordinator

Certest is a biotechnology company with extensive experience in in vitro diagnostics for human diseases and the development of advanced technologies for nucleic acid therapies. In the therapeutic field, it specializes in the design and delivery of oligonucleotide and RNA-based treatments, utilizing a state-of-the-art lipid platform for LNPs, one of the most advanced in the world.

Certest develops innovative diagnostic and therapeutic solutions to combat AMR. On the diagnostic front, Certest creates a LFIA test for the direct detection of carbapenemases from clinical samples, along with a NGS kit that includes library preparation and user-friendly bioinformatic tool for identifying bacterial resistance. On the therapeutic side, the company focuses on developing innovative cell-targeted nucleic acid therapies.

Member of the CDTI Group

Curapath is a global CDMO specialising in the custom design, development and GMP manufacturing of next-generation polymer and lipid-based drug delivery systems. Curapath investigates non-viral vectors and shielding lipids to improve LNPs, as well as develops analytical and scale-up methods for drug candidates.

Member of the CDTI Group

Levprot is an innovative SME dedicated to the design, development and implementation of protocols for the expression of enzymes and other recombinant proteins by precision fermentation in yeast cells.

Levprot works on developing an innovative method for expressing and purifying bacteriocins in genetically modified yeast, as well as generating ligands for targeted nucleic acid-based therapies.

Member of the CDTI Group

Hiberus is a leading technology consulting and IT solutions company, specialising in advanced software, data analysis and systems integration services. Hiberus works on developing an antimicrobial resistance prediction model and integrating it with NGS analysis software.

Member of the CDTI Group

Nostrum Biodiscovery is a biotechnology company focused on the identification and development of bioactive compounds with therapeutic potential through advanced computational technologies.

Nostrum Biodiscovery focuses on optimizing the design of therapeutic oligonucleotides, predicting cell receptors, and designing ligands using cutting-edge computational tools.

Member of the CDTI Group

BioClonal is a biotech company that has developed the RedMabs platform to control the immunodominance of the murine animal model, a key point in the development of improved and competitive monoclonal antibodies for diagnostic and therapeutic purposes.

BioClonal focuses on developing ultra-sensitive antibodies for use in the carbapenemase detection LFIA and designing ligands for targeted nucleic acid-based therapies.

Coordinator of the AEI Group

The mission of the Carlos III Health Institute (ISCIII) is to contribute to improving the health of all citizens and to fight against diseases. The National Microbiology Centre is participating in this project through the Antibiotic Resistance Group.

ISCIII contributes to the development of predictive software for identifying antimicrobial resistance and, in collaboration with CSIC, creates novel immunotherapies. Additionally, ISCIII assesses the effectiveness of the resulting diagnostic and therapeutic solutions.

Member of the AEI Group

The University of Zaragoza is a benchmark in teaching, research and innovation in Spain. This project involves the participation of four research groups:

• The Mycobacterial Genetics Group collaborates in the development and assessment of nucleic acid therapies against *Mycobacterium tuberculosis*.
• The Structural Biology Group of the Institute of Biocomputation and Physics of Complex Systems (BIFI-UNIZAR) contributes to the design of new receptor-binding ligands.
• The Protein Targets and Bioactive Compounds Group (ProtBioCom) is in charge of ligand characterization.
• The Physical Modeling of Biomolecules Group is responsible for the humanization of the ligands developed for targeting.

Member of the AEI Group

The University of Navarra is a private institution recognised for its excellence in research. The ‘Antimicrobial Resistance’ group participates in this project, collaborating in the design and assesment of nucleic acid-based therapies, as well as the clinical evaluation of diagnostic solutions.

Member of the AEI Group

The Ramon y Cajal Health Research Institute participates through the Specialised Group for the Study of the Human Microbiota of the Spanish Society of Infectious Diseases and Clinical Microbiology in this project to clinically assess diagnostic solutions and investigate new bacteriocins for therapeutic applications.

Member of the AEI Group

The Spanish National Research Council (CSIC) is Spain’s largest public institution dedicated to scientific and technical research. This project includes the participation of the Advanced Therapies group of the Biological Research Centre, which will lead the development of immunotherapies for treating infections caused by antimicrobial-resistant bacteria.

Member of the AEI Group

The Institute for Research in Biomedicine in Barcelona (IRB) is a biomedical research centre working towards a disease-free life. The Molecular Modelling and Bioinformatics group is actively involved in this project, focusing on stabilisation strategies for therapeutic oligonucleotides and contributing to the rational design of ligands.

Member of the AEI Group

The main objective of Fundación Para La Gestión De La Investigación En Salud De Sevilla (FISEVI) is the management of health research in hospitals and public research centers in the province of Seville, including the Instituto de Biomedicina de Sevilla (IBIS). The IBIS carries out research into the mechanisms of the most prevalent pathologies and the development of new methods of diagnosis and treatment. In this project participates contributing to the development of the predictive model and the evaluation of the resulting diagnostic and therapeutic solutions.